Cost analyses of adjunct colony stimulating factors for acute leukemia: Can they improve clinical decision making

Leukemia and Lymphoma

Volumn 37, Issue 1-2, 2000, Pages 65-70

  Bennett, Charles L ^a,b,f   Stinson, Tammy J ^a   Laver, Joseph H ^c   Bishop, Michael R ^d   Godwin, John E ^e   Tallman, Martin S ^b  

^a Chicago VA Hlthcare Syst L   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Economics; Hematopoietic colony stimulating factors; Leukemia

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; INFECTION COMPLICATION; LEUKEMIA; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; META ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0034104594     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009057629     Document Type: Article

References (20)

1. Ohno R, Tomonago M, Kobayashi T, et al. Effect of granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871; 1990.
2. Buchner T, Hiddemann W, Koenigsmann M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78:1190-97; 1991.
3. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332: 1671-83; 1995.
4. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 336:1781-87; 1997.
5. Heil G, Hoelzer D, Sanz MA, et al. A randomized double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90:4710-18; 1997.
6. Godwin JE, Kopecky K, Head DR, et al. A double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia. A Southwest Oncology Group Study. Blood 91:3607-15; 1998.
7. Rowe JM, Anderson JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Blood 86:457-62; 1995.
8. Rowe JM, Rubin A, Mazza JJ, et al. Incidence of infections in adult patients with acute myeloid leukemia treated with yeast-derived GM-CSF: Results of a double blind prospective study by the Eastern Cooperative Oncology Group. In Acute Leukemias V, Hiddemann et al. eds. Heidelberg, Germany: Springer-Verlag, 1996.
9. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-40; 1996.
10. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-03; 1994.
11. Desch CE and Ozer H. Neutropenia and neoplasia: An overview of the pharmacoeconomics of sargramostim in cancer therapy. Clin Ther 19:847-65; 1997.
12. Laver J, Amylon M, Desai S, et al. Effects of r-metHuG-CSF in an intensive treatment for T-Cell leukemia and advanced stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J Clin Oncol 16(2):522-526; 1998.
13. Bennett CL, Stinson TJ, Lane D, et al. A cost-analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic leukemia: A case for prospective economic analysis in a cooperative trial. Med Ped Onc, 1999, in press.
14. Lu ZJ, Luo R, Erder H, et al. Cost impact of filgrastim as an adjunct to chemotherapy for patients with acute myeloid leukemia. Proceedings of the American Society of Hematology 1996; 826a.
15. Bennett CL, Hynes DM, Godwin JE, et al. Economic analysis of granulocyte colony-stimulating factor as adjunct therapy for older patients with AML: Estimates from a SWOG clinical trial. Proceedings of the American Society of Hematology, 1998; 2538a.
16. Bennett CL, Stinson TJ, Tallman MS, et al. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factro in adult patients with acute myelogenous leukemia. Ann Oncol 10:177-82; 1999.
17. The American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic growth factors: evidence based clinical practice guidelines. J Clin Oncol 12: 2471-2508, 1994.
18. The American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 14: 1957-1960; 1996.
19. Drummond MF, Menzin J, Oster G. Problems in undertaking pharmacoenomic assessments in phase III clinical trials: The case of colony stimulating factors. In Quality of Life and Pharmacoenomics in Clinical Trials, B Spilker ed. Phila, Pa: Lippincott-Raven Publishers, 1996.
20. Hillner BE, Smith TJ. Does a clinical trial warrant an economic analysis. J Natl Cancer Inst 90: 724-5; 1998.